Continuous Manufacturing (Pharmaceuticals & Biopharmaceuticals) Market To Reach $3.4 Billion By 2033

October 2026 | Report Format: Electronic (PDF)

Continuous Manufacturing (Pharmaceuticals & Biopharmaceuticals) Market Growth & Trends

The global continuous manufacturing (pharmaceuticals & biopharmaceuticals) market size is expected to reach USD 3.4 billion by 2033, registering a CAGR of 11.0% from 2026 to 2033, according to a new report by Grand View Research, Inc. Although batch manufacturing is the dominant mode of product development within the pharma and biopharma industry, the companies have begun shifting their focus toward continuous manufacturing (CM). The key drivers for the transition from batch to continuous manufacturing include drug shortage, more stringent requirements for consistent quality, the need for reduced processing costs, and the demand for higher and improved productivity.

Regulatory authorities are increasingly supportive of this therapeutic development model. They are encouraging the adoption of CM through releasing drafts and guidelines. Moreover, the presence of communities and organizations that are devoted to the commercialization of this market within the pharma and biopharma sector is driving the revenue. CCP Summit 2020 is one of such summits that is engaged in exploring scientific and technological advancements to address the technology challenges and accelerate upfront investment in the market.

In addition, the growing demand for biosimilars and an ever-increasing pressure for reducing drug development costs have driven the interest of biopharma players in this space. With a plethora of research activities available on making individual unit operations continuous, studies are also conducted to explore the possibility of a continuous end-to-end development process. Ongoing research efforts in this area are anticipated to greatly favor the revenue growth in the coming years.

Based on mode, in-house pharmaceutical companies are anticipated to witness lucrative growth in the coming years owing to the shift of well-established pharma players toward the continuous manufacturing market. On the basis of scale, the clinical and preclinical scale manufacturing segments collectively captured a significant revenue share in 2020 owing to the easy integration of systems and a high number of ongoing R&D activities.

North America led the global market in 2020. This is attributed to the presence of key technology developers as well as high R&D expenditure in drug development by the end-users in the U.S. Key players are implementing various strategies to strengthen their product offerings and offer diverse technologically advanced products to accelerate therapeutics development.

key Request a free sample copy or view report summary: Continuous Manufacturing Market In Pharmaceuticals & Biopharmaceuticals Report

Continuous Manufacturing (Pharmaceuticals & Biopharmaceuticals) Market Report Highlights

The large molecules segment dominated the market, with the largest revenue share of 79.5% in 2025, supported by the widespread use of perfusion cell culture, continuous chromatography, and integrated downstream processing in the manufacture of monoclonal antibodies and other biologics.
The end product manufacturing segment led the market with the largest revenue share of 53.7% in 2025 and is expected to grow at the fastest CAGR of 11.1% over the forecast period, supported by the adoption of continuous granulation, drying, blending, and compression lines for finished dosage forms.
The solid dosage manufacturing segment accounted for the largest revenue share of 66.3% in 2025, as tablets and capsules were the first products approved using continuous manufacturing and remain the main application for continuous granulation, drying, and compression equipment.
The preclinical segment dominated the market with the largest revenue share of 40.9% share in 2025, making it the leading scale segment, as drug developers increasingly build continuous processes early in development to avoid later process changes.
The contract segment led the market with the largest revenue share of 59.6% in 2025 and is expected to grow at the fastest CAGR of 11.1% over the forecast period, as many drug developers prefer to access continuous manufacturing capacity through CDMOs rather than invest in dedicated lines.
The semi-continuous systems segment led the market with the largest revenue share of 58.5% in 2025 and is expected to grow at the fastest CAGR of 11.3% over the forecast period, as manufacturers often adopt continuous unit operations step by step before investing in fully integrated lines.
The North America continuous manufacturing (pharmaceuticals & biopharmaceuticals) market held the largest revenue share of 36.8% in 2025, supported by the presence of major pharmaceutical companies and equipment suppliers, a large number of products approved using continuous manufacturing, and active FDA programs for emerging and advanced manufacturing technologies.

Continuous Manufacturing (Pharmaceuticals & Biopharmaceuticals) Market Segmentation

Grand View Research has segmented the global continuous manufacturing (pharmaceuticals & biopharmaceuticals) market report based on the therapeutic type, application, formulation, scale, mode, product, and region:

Continuous Manufacturing (Pharmaceuticals & Biopharmaceuticals) Therapeutics Type Outlook (Revenue, USD Billion, 2021 - 2033)

Large Molecules
Small Molecules

Continuous Manufacturing (Pharmaceuticals & Biopharmaceuticals) Application Outlook (Revenue, USD Billion, 2021 - 2033)

End Product Manufacturing
API Manufacturing

Continuous Manufacturing (Pharmaceuticals & Biopharmaceuticals) Formulation Outlook (Revenue, USD Billion, 2021 - 2033)

Solid Dosage Manufacturing
Liquid Dosage Manufacturing

Continuous Manufacturing (Pharmaceuticals & Biopharmaceuticals) Scale Outlook (Revenue, USD Billion, 2021 - 2033)

Preclinical
Clinical
Commercial

Continuous Manufacturing (Pharmaceuticals & Biopharmaceuticals) Mode Outlook (Revenue, USD Billion, 2021 - 2033)

Contract
In-house

Continuous Manufacturing (Pharmaceuticals & Biopharmaceuticals) Product Outlook (Revenue, USD Billion, 2021 - 2033)

Semi-Continuous Systems
- Continuous Granulators
- Other Semi-Continuous Systems
- Continuous Dryers
- Continuous Coaters
- Continuous Blenders
- Continuous Compressors
Integrated Systems
Others